These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1144070)

  • 1. [Immunological factors in the origin and development of neoplasms. I].
    Steffin J
    Nowotwory; 1975; 25(2):123-33. PubMed ID: 1144070
    [No Abstract]   [Full Text] [Related]  

  • 2. How efficient is immunological surveillance against cancer and why does it fail?
    Laroye GJ
    Lancet; 1974 Jun; 1(7866):1097-1100. PubMed ID: 4135256
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tumor antigens and immune reactions against tumors].
    Trepel F
    Med Klin; 1971 Feb; 66(7):215-22. PubMed ID: 4928396
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tumor immunology].
    Cerni CM
    Subsid Med; 1974; 2():21-5. PubMed ID: 4606048
    [No Abstract]   [Full Text] [Related]  

  • 5. Current aspects of tumor immunology. Preface and introduction.
    Weiss DW
    Isr J Med Sci; 1973 Mar; 9(3):205-16. PubMed ID: 4575649
    [No Abstract]   [Full Text] [Related]  

  • 6. IMMUNOLOGICAL TOLERANCE AND THE CANCER PROBLEM.
    HASEK M; SVOBODA J; KOLDOVSKY P
    Philipp J Cancer; 1963; 5():535-9. PubMed ID: 14232627
    [No Abstract]   [Full Text] [Related]  

  • 7. [Specific neoplastic antigens].
    Dux K
    Pol Arch Med Wewn; 1970; 45(6):745-53. PubMed ID: 5505267
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor-specific immune mechanisms.
    Smith RT
    N Engl J Med; 1968 Jun; 278(24):1326-31 concl. PubMed ID: 4869875
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current and prospective problems in tumor immunology].
    Pitzurra M
    Boll Ist Sieroter Milan; 1971; 50(3):209-20. PubMed ID: 4947785
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunological processes and their morphological manifestations in the development of tumors].
    Ageev AK
    Arkh Patol; 1974; 36(6):72-80. PubMed ID: 4137423
    [No Abstract]   [Full Text] [Related]  

  • 11. On the nature of cancer. An analysis from concepts in current research.
    Richards V
    Oncology; 1967; 21(3):161-88. PubMed ID: 5584150
    [No Abstract]   [Full Text] [Related]  

  • 12. [3d and final discourse on the new interpretation of the problem of tumors].
    Spirito A
    Riv Biol; 1971; 64(2):107-70. PubMed ID: 5143718
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunological facilitation, a broadening of the concept of the enhancement phenomenon.
    Voisin GA
    Prog Allergy; 1971; 15():328-485. PubMed ID: 4151281
    [No Abstract]   [Full Text] [Related]  

  • 14. [IMMUNOLOGICAL TOLERANCE AND ITS SIGNIFICANCE IN MEDICAL RESEARCH].
    SERRE A
    Montp Med; 1963 Nov; 64():159-69. PubMed ID: 14200867
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor immunology.
    McKhann CF; Yarlott MA
    CA Cancer J Clin; 1975; 25(4):187-97. PubMed ID: 805638
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunological phenomena and carcinogenesis].
    Srebro Z
    Postepy Hig Med Dosw; 1971; 25(3):391-414. PubMed ID: 5571144
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunology of tumors].
    Clerici E
    Minerva Nefrol; 1983; 30(2 Suppl):13-8. PubMed ID: 6866320
    [No Abstract]   [Full Text] [Related]  

  • 18. [Immunological approaches to the treatment of solid tumors].
    May-Levin F
    Boll Ist Sieroter Milan; 1971; 50(3):221-30. PubMed ID: 4111987
    [No Abstract]   [Full Text] [Related]  

  • 19. CYBERNETICS, MICROORGANISMS AND NEOPLASTIC DISEASE.
    HADLEY HG
    Oncologia; 1964; 17():221-6. PubMed ID: 14154024
    [No Abstract]   [Full Text] [Related]  

  • 20. Malignant lymphomas following allogenic disease: transition from an immunological to a neoplastic disorder.
    Schwartz RS; Beldotti L
    Science; 1965 Sep; 149(3691):1511-4. PubMed ID: 5828031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.